Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model

Stroke. 2001 Jun;32(6):1336-40. doi: 10.1161/01.str.32.6.1336.

Abstract

Background and purpose: We used a rat model of thromboembolic stroke to evaluate whether hypertension increases the incidence of hemorrhage after fibrinolysis with tissue plasminogen activator (tPA).

Methods: In this model, a microclot suspension was injected into the middle cerebral artery territory to induce focal ischemia. Reperfusion was induced in spontaneously hypertensive rats (SHR) by administering tPA (10 mg/kg) intravenously at 2 hours or 6 hours after the onset of thromboembolic focal ischemia. In untreated control rats, saline was administered at 2 hours after ischemia.

Results: Hemorrhagic transformation was observed only in rats that received tPA at 6 hours (6 of 8 rats [75%]). Reduction of mean arterial blood pressure from 122+/-3 to 99+/-2 mm Hg with hydralazine, given to SHR for 1 week before ischemia, significantly decreased the incidence of hemorrhage in 2 of 11 rats (18%). tPA reduced infarct volumes, but cotreatment with hydralazine did not result in further protection.

Conclusions: This study demonstrates that in this rat thromboembolic model of stroke, tPA-induced hemorrhage is dependent on blood pressure and that pharmacological reduction of hypertension during fibrinolysis can reduce the risk of hemorrhagic transformation.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Blood Flow Velocity / drug effects
  • Blood Gas Analysis
  • Blood Pressure / drug effects
  • Brain / blood supply
  • Brain / pathology
  • Cerebral Hemorrhage / etiology*
  • Cerebral Hemorrhage / pathology
  • Cerebral Hemorrhage / prevention & control
  • Cerebrovascular Circulation / drug effects
  • Disease Models, Animal
  • Drug Administration Schedule
  • Hydralazine / administration & dosage
  • Hypertension / complications*
  • Hypertension / drug therapy
  • Incidence
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / pathology
  • Intracranial Thrombosis / complications*
  • Intracranial Thrombosis / drug therapy
  • Laser-Doppler Flowmetry
  • Male
  • Rats
  • Rats, Inbred SHR
  • Stroke / complications*
  • Stroke / drug therapy
  • Stroke / pathology
  • Thrombolytic Therapy* / adverse effects
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Hydralazine
  • Tissue Plasminogen Activator